Review
Molecular Aspects of Renal Handling of Aminoglycosides and Strategies for Preventing the Nephrotoxicity

https://doi.org/10.2133/dmpk.19.159Get rights and content

Summary:

Aminoglycosides such as gentamicin and amikacin are the most commonly used antibiotics worldwide in the treatment of Gram-negative bacterial infections. However, serious complications like nephrotoxicity and ototoxicity are dose-limiting factors in the use of aminoglycosides. A relatively large amount of the intravenously administered dose is accumulated in the kidney (about 10% of dose), whereas little distribution of aminoglycosides to other tissues is observed. Aminoglycosides are taken up in the epithelial cells of the renal proximal tubules and stay there for a long time, resulting in nephrotoxicity. Acidic phospholipids are considered as a binding site for aminoglycosides in the brush-border membrane of the proximal tubular cells. More recently, it has been reported that megalin, a giant endocytic receptor abundantly expressed at the apical membrane of renal proximal tubules, plays an important role in binding and endocytosis of aminoglycosides in the proximal tubular cells. The elucidation of the aminoglycoside-binding receptor would help design a strategy to prevent against aminoglycoside-induced nephrotoxicity. In this review, we summarize recent advances in the understandings of the molecular mechanisms responsible for renal accumulation of aminoglycosides, especially megalin-mediated endocytosis. In addition, approaches toward prevention of aminoglycoside-induced nephrotoxicity are discussed, based on the molecular mechanisms of the renal accumulation of aminoglycosides.

References (108)

  • W.J. Chen et al.

    NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low-density lipoprotein receptor

    J. Biol. Chem.

    (1990)
  • X.X. Xu et al.

    Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product

    J. Biol. Chem.

    (1995)
  • E.I. Christensen et al.

    Membrane receptors for endocytosis in the renal proximal tubule

    Int. Rev. Cytol.

    (1998)
  • S.K. Moestrup et al.

    Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes

    J. Biol. Chem.

    (1993)
  • J.R. Leheste et al.

    Megalin knockout mice as an animal model of low molecular weight proteinuria

    Am. J. Pathol.

    (1999)
  • A. Nykjaer et al.

    An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3

    Cell

    (1999)
  • M. Takano et al.

    Cisplatin-induced inhibition of receptor-mediated endocytosis of protein in the kidney

    Kidney Int.

    (2002)
  • X.Y. Zhai et al.

    Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney

    Kidney Int.

    (2000)
  • P.J. Verroust et al.

    The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology

    Kidney Int.

    (2002)
  • C. Schmitz et al.

    Megalin deficiency offers protection from renal aminoglycoside accumulation

    J. Biol. Chem.

    (2002)
  • A. Watanabe et al.

    Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor an tagonists

    J. Control. Release

    (2004)
  • P.A. Janmey et al.

    Phosphoinositide-binding peptides derived from the sequences of gelsolin and villin

    J. Biol. Chem.

    (1992)
  • B.H. Ali

    Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research

    Food Chem. Toxicol.

    (2003)
  • K.D. Bass et al.

    Pharmacokinetics of once-daily gentamicin dosing in pediatric patients

    J. Pediatr. Surg.

    (1998)
  • J.E. Martin

    Once-daily aminoglycoside dosing: where are we now?

    J. Crit. Care

    (2003)
  • K. Mizuta et al.

    Ultrastructural localization of megalin in the rat cochlear duct

    Hearing Res.

    (1999)
  • E. Hashino et al.

    Endocytosis of aminoglycoside antibiotics in sensory hair cells

    Brain Res.

    (1995)
  • M.M. Sousa et al.

    Evidence for the role of megalin in renal uptake of transthyretin

    J. Biol. Chem.

    (2000)
  • S. Stefansson et al.

    Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100

    J. Biol. Chem.

    (1995)
  • M.Z. Kounnas et al.

    Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin

    J. Biol. Chem.

    (1995)
  • H.F. Chambers

    The aminoglycosides

  • M.P. Mingeot-Leclercq et al.

    Aminoglycosides: nephrotoxicity

    Antimicrob. Agents Chemother.

    (1999)
  • M. Just et al.

    The renal handling of polybasic drugs. 1. Gentamicin and aprotinin in intact animals

    Naunyn-Schmiedeberg’s Arch. Pharmacol.

    (1977)
  • H. Saito et al.

    Mechanisms of gentamicin transport in kidney epithelial cell line (LLC-PK1)

    J. Pharmacol. Exp. Ther.

    (1986)
  • K. Inui et al.

    Aminoglycoside-induced alterations in apical membranes of kidney epithelial cell line (LLC-PK1)

    Am. J. Physiol.

    (1988)
  • R. Hori et al.

    Surface binding and intracellular uptake of gentamicin in the cultured kidney epithelial cell line (LLC-PK1)

    J. Pharmacol. Exp. Ther.

    (1992)
  • M. Takano et al.

    Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line

    J. Pharmacol. Exp. Ther.

    (1994)
  • C. Josepovitz et al.

    Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations

    J. Pharmacol. Exp. Ther.

    (1982)
  • R.A. Giuliano et al.

    In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats

    J. Pharmacol. Exp. Ther.

    (1986)
  • B.A. Molitoris

    Cell biology of aminoglycoside nephrotoxicity: newer aspects

    Curr. Opin. Nephrol. Hypertens.

    (1997)
  • J. Schacht

    Isolation of an aminoglycoside receptor from guinea pig inner ear tissues and kidney

    Arch. Otorhinolaryngol.

    (1979)
  • M. Just et al.

    The renal handling of polybasic drugs. 2. In vitro studies with brush border and lysosomal preparations

    Naunyn-Schmiedeberg’s Arch. Pharmacol.

    (1977)
  • J.J. Lipsky et al.

    Gentamicin uptake by renal tubule brush border membrane vesicles

    J. Pharmacol. Exp. Ther.

    (1980)
  • M. Sastrasinh et al.

    Identification of the aminoglycoside binding site in rat renal brush border membranes

    J. Pharmacol. Exp. Ther.

    (1982)
  • G.J. Kaloyanides

    Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity

    Ren. Fail.

    (1992)
  • P.D. Williams et al.

    Correlation between renal membrane binding and nephrotoxicity of aminoglycosides

    Antimicrob. Agents Chemother.

    (1987)
  • P.D. Williams et al.

    Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides

    J. Pharmcol. Exp. Ther.

    (1986)
  • L.S. Ramsammy et al.

    Polyaspartic acid protects against gentamicin nephrotoxicity in the rat

    J. Pharmcol. Exp. Ther.

    (1989)
  • B.K. Kishore et al.

    Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats

    J. Pharmacol. Exp. Ther.

    (1992)
  • J.H. Todd et al.

    Renal brush border membrane vesicle aminoglycoside binding and nephrotoxicity

    J. Pharmacol. Exp. Ther.

    (1995)
  • Cited by (247)

    • The role of oxidative stress in kidney diseases

      2022, Novel Therapeutic Approaches Targeting Oxidative Stress
    • Connexin hemichannel inhibitors with a focus on aminoglycosides

      2021, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      Their continued use despite their ototoxicity and nephrotoxicity is due to their efficacy and low cost. Ototoxicity and nephrotoxicity are relatively common but can be managed to some degree by a single daily dose administration and therapeutic drug monitoring [246–248]. Although the details on the mechanisms of ototoxicity and nephrotoxicity have not been elucidated, they are probably multifactorial and involve the generation of reactive oxygen species and nitric oxide [249–251].

    View all citing articles on Scopus
    View full text